CNS Summit Announces Sanofi as No. 1 in the 2026 Digital Innovation Index
Article excerpt
Highlighted: the sentence this signal was extracted from
BOSTON, Nov. 4, 2026 /PRNewswire/ -- Sanofi ranked first in the 2026 CNS Summit Digital Innovation Index, developed in collaboration with IDEA Pharma, a division of SAI MedPartners, placing in the top three in all three categories. The rankings were revealed today on the CNS Summit 2026 main stage at Encore Boston Harbor. Now in its 11th year, the Index ranks the top 30 pharmaceutical companies on digital innovation, using publicly reported initiatives and investments from July 2025 through July 2026. The 2026 top 10 are Sanofi, Eli Lilly, AstraZeneca, Chugai, Roche, Bristol Myers Squibb, Novo Nordisk, Johnson & Johnson, Boehringer Ingelheim and Merck KGaA. Category leaders were Roche in commercial, Novo Nordisk in clinical development and Recursion in research. "Ranking first in the Pharmaceutical Digital Innovation Index reflects a shift we are proud of: digital and AI at Sanofi are now a connected system spanning research, clinical development and commercial operations. This is what allows us to move beyond AI experimentation to AI that delivers impact at scale, so that scientific breakthroughs reach patients faster," said Emmanuel Frenehard, Chief Digital Officer, Sanofi. CNS Summit's Chairman and Chief Curator, Dr. Amir Kalali, said, "Digital innovation is becoming more and more important in research and development. We are pleased to continue to support this...
Keep reading with a free account
The rest of this article, and every signal for Sanofi, is in your free account.